News

How Certain Bacteria Resist Antibiotics to Become Virulent in CF and Other Diseases Focus of Thesis

A deeper understanding of how bacteria like Pseudomonas aeruginosa acts and survives in people despite antibiotic treatment was the focus of a doctoral thesis, along with a recommendation for antibiotic combinations that might work better those what’s currently in use. The thesis, “Host-pathogen interactions in Pseudomonas aeruginosa invasive and respiratory tract infection,” is by…

Phase 2 Study of Oral Acebilustat in Treating Lung Inflammation Fully Enrolled in US, Europe

Celtaxsys announced it has completed enrollment of its Phase 2b clinical trial evaluating the company’s lead anti-inflammatory candidate, oral acebilustat, in adult patients with cystic fibrosis (CF). Acebilustat (formerly known as CTX-4430) is a once-daily, oral anti-inflammatory being evaluated for its safety and efficacy in treating diseases like CF. It is a new small…

X-Chem, Vertex to Jointly Develop Small Molecules for CF, Other Severe Genetic Diseases

X-Chem Pharmaceuticals and Vertex Pharmaceuticals will jointly develop small molecules targeting cystic fibrosis (CF) and other severe genetic diseases. Under the collaboration announced May 16, X-Chem will apply its proprietary DEX libraries — which holds more than 120 billion small compounds — to discover new drug candidates against targets involved in CF…